An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases
- J. Clin. Endocrinol. Metab., Published online before print July 18, 2006, doi: 10.1210/jc.2005-2845